- Home
- CTO vs ORIC Comparison
CTO vs ORIC Comparison
Compare CTO & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | ORIC |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 837.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTO | ORIC |
|---|---|---|
| Price | $19.74 | $10.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $21.50 | $19.73 |
| AVG Volume (30 Days) | 178.4K | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $4.52 |
| 52 Week High | $20.25 | $14.93 |
Technical Indicators
Market Signals| Indicator | CTO | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 65.12 | 46.78 |
| Support Level | $19.16 | $9.75 |
| Resistance Level | $19.82 | $10.79 |
| Average True Range (ATR) | 0.31 | 0.98 |
| MACD | 0.12 | 0.06 |
| Stochastic Oscillator | 96.63 | 52.24 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.